<DOC>
	<DOC>NCT00516724</DOC>
	<brief_summary>The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with carboplatin and/or Paclitaxel chemotherapy</brief_summary>
	<brief_title>Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
	<criteria>Male or female patients with a histologically or cytologically diagnosed malignant solid tumour Adequate bone marrow, hepatic and renal function Performance status of no more than 2 ( ECOG scale). Any chemotherapy, radiotherapy ( except palliative), endocrine or immunotherapy within 4 weeks prior to entry Major surgery with 4 weeks of entering the study and must have recovered from effects of the major surgery More than two previous courses of platinumcontaining chemotherapy Heavily pretreated patients(&gt; 2 courses of previous chemotherapy and/or extensive irradiation leading to bone marrow deficiency) will be excluded from the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>malignant solid tumours</keyword>
	<keyword>Poly(ADP ribose) polymerases</keyword>
</DOC>